Thromboelastography maximum amplitude predicts short-term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure.
acute-on-chronic liver failure
hepatitis B
maximum amplitude
platelet
thromboelastography
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
27
07
2019
accepted:
29
05
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
ppublish
Résumé
Patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) exhibit complex hemostatic defects. Thromboelastography (TEG) can be used to reveal global hemostasis in patients with liver disease; however, little is known about the association between TEG and the outcome of patients with HBV-related ACLF. The present study aimed to investigate the value of TEG for predicting 90 day mortality in patients with HBV-related ACLF. A total of 51 patients with HBV-related ACLF, 26 patients with chronic hepatitis B (CHB) and 26 healthy controls (HC) were enrolled in the present study. TEG, standard coagulation tests, routine blood tests, biochemical markers and demographic variables were recorded and assessed for prognostic value. The results indicated that a prolonged reaction and kinetics (K) time, a shortened α angle and a decreased maximum amplitude (MA) and coagulation index (CI) were observed in patients with HBV-related ACLF, compared with CHB and HC subjects. Patients with HBV-related ACLF in the mortality group exhibited a decrease in α angle, MA, lysis at 30 min, CI, fibrinogen and platelet count, and an increase in K time, international normalized ratio (INR) and the model for end-stage liver disease (MELD) score in comparison with the survival group. MA and INR were two independent predictors of 90 day mortality in patients with HBV-related ACLF, with hazard ratios of 0.918 (95% CI, 0.867-0.971; P=0.003) and 3.141 (95% CI, 1.843-5.354; P<0.001) respectively. When predicting 90 day mortality, MA + INR exhibited the highest area under the receiver operating characteristic curve, followed by INR, MELD score and MA. Patients with ACLF and MA ≤51.5 mm exhibited a poorer outcome than those with MA >51.5 mm, as revealed via the Kaplan-Meier analysis. In summary, the findings of the present study suggested that TEG MA was associated with 90 day mortality in patients with HBV-related ACLF, and a combination of MA and INR was superior to MA, INR and MELD score in terms of prognostic value.
Identifiants
pubmed: 32765759
doi: 10.3892/etm.2020.8990
pii: ETM-0-0-8990
pmc: PMC7401745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2657-2664Informations de copyright
Copyright: © Zhu et al.
Références
Hepatology. 2018 Dec;68(6):2325-2337
pubmed: 29790188
Platelets. 2018 Jul;29(5):520-527
pubmed: 28895774
Semin Thromb Hemost. 2015 Jul;41(5):474-80
pubmed: 26049070
Transplant Proc. 2010 Sep;42(7):2590-3
pubmed: 20832550
Medicine (Baltimore). 2017 Apr;96(17):e6802
pubmed: 28445322
J Crit Care. 2018 Feb;43:54-60
pubmed: 28843665
Saudi J Gastroenterol. 2015 May-Jun;21(3):165-74
pubmed: 26021776
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):971-80
pubmed: 27070325
Hepatol Int. 2014 Oct;8(4):453-71
pubmed: 26202751
Transplant Proc. 2018 Dec;50(10):3552-3558
pubmed: 30577236
J Viral Hepat. 2016 Nov;23(11):920-929
pubmed: 27397610
Ann Lab Med. 2017 May;37(3):204-212
pubmed: 28224766
Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):341-350
pubmed: 29334786
Transfus Apher Sci. 2009 Apr;40(2):119-23
pubmed: 19249246
Liver Int. 2019 Apr;39(4):694-704
pubmed: 30589495
Ann Hepatol. 2018 Apr 9;17(3):392-402
pubmed: 29735787
J Crit Care. 2017 Apr;38:215-224
pubmed: 27978499
Clin Gastroenterol Hepatol. 2016 Apr;14(4):613-620.e4
pubmed: 26453953
Gut. 1998 Aug;43(2):267-71
pubmed: 10189856
Semin Thromb Hemost. 2018 Mar;44(2):114-125
pubmed: 28898899
Hepatology. 2016 Feb;63(2):566-73
pubmed: 26340411
Int J Obstet Anesth. 2006 Jan;15(1):7-12
pubmed: 16256341
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
J Thromb Haemost. 2012 Jul;10(7):1312-9
pubmed: 22568491
Exp Ther Med. 2017 Jan;13(1):285-289
pubmed: 28123503
N Engl J Med. 2011 Jul 14;365(2):147-56
pubmed: 21751907
Hepatology. 2015 Jul;62(1):232-42
pubmed: 25800029
Ann Hepatol. 2018 Oct 16;17(6):1042-1051
pubmed: 30600294
Gastroenterol Hepatol (N Y). 2012 Aug;8(8):513-20
pubmed: 23293564
Gut. 2018 Dec;67(12):2181-2191
pubmed: 28928275
Transplant Proc. 2017 Nov;49(9):2110-2116
pubmed: 29149970